Abeona Therapeutics (NASDAQ:ABEO) CEO Vishwas Seshadri Sells 25,000 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of the company’s stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $5.24, for a total transaction of $131,000.00. Following the transaction, the chief executive officer owned 1,190,067 shares in the company, valued at approximately $6,235,951.08. This trade represents a 2.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Vishwas Seshadri also recently made the following trade(s):

• On Monday, September 29th, Vishwas Seshadri sold 19,274 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.39, for a total transaction of $103,886.86.
• On Wednesday, July 9th, Vishwas Seshadri sold 69,420 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.86, for a total transaction of $406,801.20.

Abeona Therapeutics Stock Performance

NASDAQ:ABEO opened at $5.28 on Thursday. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.54. The firm has a fifty day simple moving average of $6.41 and a 200-day simple moving average of $5.92. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $270.76 million, a P/E ratio of 7.54 and a beta of 1.43.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $21.71 million. On average, equities research analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Corient Private Wealth LLC acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth approximately $127,000. Squarepoint Ops LLC boosted its holdings in Abeona Therapeutics by 274.2% during the second quarter. Squarepoint Ops LLC now owns 141,978 shares of the biopharmaceutical company’s stock worth $806,000 after buying an additional 104,037 shares in the last quarter. Man Group plc acquired a new stake in Abeona Therapeutics during the second quarter valued at $67,000. BNP Paribas Financial Markets purchased a new position in Abeona Therapeutics in the second quarter valued at $749,000. Finally, Boone Capital Management LLC acquired a new position in shares of Abeona Therapeutics in the second quarter worth about $7,126,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABEO has been the topic of a number of recent research reports. Oppenheimer upped their target price on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Friday, August 15th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, August 18th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Abeona Therapeutics has a consensus rating of “Buy” and a consensus target price of $19.50.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.